Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis
Lars Johan Nissen, … , Ebba Bråkenhielm, Yihai Cao
Lars Johan Nissen, … , Ebba Bråkenhielm, Yihai Cao
Published October 1, 2007
Citation Information: J Clin Invest. 2007;117(10):2766-2777. https://doi.org/10.1172/JCI32479.
View: Text | PDF
Research Article

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis

  • Text
  • PDF
Abstract

Tumors produce multiple growth factors, but little is known about the interplay between various angiogenic factors in promoting tumor angiogenesis, growth, and metastasis. Here we show that 2 angiogenic factors frequently upregulated in tumors, PDGF-BB and FGF2, synergistically promote tumor angiogenesis and pulmonary metastasis. Simultaneous overexpression of PDGF-BB and FGF2 in murine fibrosarcomas led to the formation of high-density primitive vascular plexuses, which were poorly coated with pericytes and VSMCs. Surprisingly, overexpression of PDGF-BB alone in tumor cells resulted in dissociation of VSMCs from tumor vessels and decreased recruitment of pericytes. In the absence of FGF2, capillary ECs lacked response to PDGF-BB. However, FGF2 triggers PDGFR-α and -β expression at the transcriptional level in ECs, which acquire hyperresponsiveness to PDGF-BB. Similarly, PDGF-BB–treated VSMCs become responsive to FGF2 stimulation via upregulation of FGF receptor 1 (FGFR1) promoter activity. These findings demonstrate that PDGF-BB and FGF2 reciprocally increase their EC and mural cell responses, leading to disorganized neovascularization and metastasis. Our data suggest that intervention of this non-VEGF reciprocal interaction loop for the tumor vasculature could be an important therapeutic target for the treatment of cancer and metastasis.

Authors

Lars Johan Nissen, Renhai Cao, Eva-Maria Hedlund, Zongwei Wang, Xing Zhao, Daniel Wetterskog, Keiko Funa, Ebba Bråkenhielm, Yihai Cao

×

Figure 1

Reciprocal regulation of proliferation and migration of ECs and VSMCs.

Options: View larger image (or click on image) Download as PowerPoint
Reciprocal regulation of proliferation and migration of ECs and VSMCs.
(...
(A) BCE cell proliferation. BCE cells were pretreated with FGF2 (F) or PDGF-BB (P), followed by stimulation with either FGF2 or PDGF-BB. Cell proliferation was measured 72 hours after treatment by counting cell numbers. (B) Migration of FGF2- or PDGF-BB–pretreated BCE cells were assayed in Boyden chambers for 4 hours in the presence and absence of STI571. Migrating cells were counted under a light microscope. (C–F) Rat VSMCs (C) and BCE cells (E) were immunostained with an anti–α-SMA antibody. Uptake of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynaine perchlorate–labeled Ac-LDL by VSMCs (D) and BCE cells (F) was analyzed. (G and H) VSMC proliferation (G) and migration (H) stimulated by FGF2 and/or PDGF-BB. The data represent means of average determinants ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Scale bar: 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts